News
H1 2022: Temporary supply constraints slow down strong demand
H1 2022: Temporary supply constraints slow down strong demand
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)
Finalization of Vifor Pharma acquisition
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005796/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Evolva with strong business momentum in 1H 2022, announcing targets of mid-term plan
Evolva with strong business momentum in 1H 2022, announcing targets of mid-term plan
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-News: BB BIOTECH AG: First signs of increased M&A activity due to attractive valuations
DGAP-News: BB BIOTECH AG: First signs of increased M&A activity due to attractive valuations
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs)
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs)
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
Extension of the postponement of the settlement of Vifor Pharma tender offer
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006199/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form
Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)
Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)
COLTENE announces 2022 half-year results and outlook
COLTENE announces 2022 half-year results and outlook
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Annual General Shareholders’ Meeting 2022: Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2022:
Sonova shareholders approve all motions of the Board of Directors
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil
Annual General Meeting of Kuros Biosciences approves all resolutions
Annual General Meeting of Kuros Biosciences approves all resolutions
Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001
Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001
Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment
Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment